After Brexit: new directions for clinical trials

A new regime for clinical trials in Europe is coming into force in 2018. However, there are uncertainties about what clinical trials legislation will apply in the UK once it leaves the EU. This article is a brief summary of the changes that will come into force for businesses based in Europe and for global businesses running clinical trials in Europe, and the potential impact of Brexit.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

What 2020 means for the life sciences

15 December 2020 Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Big Pharma

Life sciences industry calls for Brexit transition period

29 November 2017 The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

Big Pharma

EMA voices ‘serious concerns’ over MA holders’ Brexit preparedness

11 July 2018 The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

More on this story

Big Pharma

What 2020 means for the life sciences

15 December 2020 Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Big Pharma

Life sciences industry calls for Brexit transition period

29 November 2017 The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

Big Pharma

EMA voices ‘serious concerns’ over MA holders’ Brexit preparedness

11 July 2018 The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

More on this story

Big Pharma

What 2020 means for the life sciences

15 December 2020 Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Big Pharma

Life sciences industry calls for Brexit transition period

29 November 2017 The EU and UK must make progress in Brexit negotiations “as soon as possible”, according to the associations that represent the European and British life sciences industry.

Big Pharma

EMA voices ‘serious concerns’ over MA holders’ Brexit preparedness

11 July 2018 The European Medicines Agency has expressed concerns about how prepared medical marketing authorisation holders are for when the UK leaves the EU.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

After Brexit: new directions for clinical trials

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features